- Home
- GLO vs CATX Comparison
GLO vs CATX Comparison
Compare GLO & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLO | CATX |
|---|---|---|
| Founded | 2006 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.3M | 211.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GLO | CATX |
|---|---|---|
| Price | $5.92 | $4.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.56 |
| AVG Volume (30 Days) | 170.5K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 11.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,075,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.08 | $1.60 |
| 52 Week High | $5.18 | $5.39 |
Technical Indicators
Market Signals| Indicator | GLO | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 57.01 | 76.41 |
| Support Level | $5.88 | $2.55 |
| Resistance Level | $5.99 | $2.78 |
| Average True Range (ATR) | 0.06 | 0.46 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 35.19 | 52.94 |
Price Performance
Historical ComparisonAbout GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.